A Study to Evaluate the Effectiveness and Safety of MEDI2070 in Subjects with Active Moderate to Severe Crohn's Disease

Overview

Información sobre este estudio

The purpose of this study is to evaluate the effectiveness and safety of MEDI2070 in subjects with moderate to severe crohn's disease who have failed or are intolerant to anti-tumor necrosis-factor-alpha therapy.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Diagnosis of ileal, ileo-colonic, or colonic Crohn's Disease (CD) for > 3 months prior to screening
  • Men or women
  • Age 18 - 80 years at the time of screening
  • Moderate to severely active CD, as defined by Crohn's Disease Activity Index (CDAI) AND endoscopic demonstration of inflammation
  • Stable dose of medications for Crohn's disease therapy
  • Prior treatment failure or intolerance with at least one Anti-Tumor Necrosis-Factor-Alpha Therapy (anti-TNF α) agent
  • Effective contraception from screening and for 36 weeks after the last dose of investigational product, including for female partners of male study subjects
  • No known history of active tuberculosis (TB) & negative assessment for TB/latent TB

Exclusion Criteria

  • Severe underlying immunosuppression
  • Severe gastrointestinal complications e.g., short bowel syndromes, obstructing strictures, recent or planned bowel surgery, Ileostomy and/or colostomy, recent bowel perforation
  • Significant infections at screening
    • Infected abscess, positive for Clostridium difficile, recent infectious hospitalization
  • Recent treatment with approved or investigational biologic therapy for Crohn's disease
  • Recent or planned live attenuated vaccine
  • History of cancer, except for basal cell carcinoma or CIS of the cervix with apparent cure ≥ 12 months before screening
  • Pregnancy/breast feeding
  • Drug abuse

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Edward Loftus, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20267875

Mayo Clinic Footer